A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND 7921) (NSC 704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC 752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.

Next Previous
Trial Profile

A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND 7921) (NSC 704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC 752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Fosbretabulin (Primary) ; Bevacizumab
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 31 Oct 2016 Post-hoc analysis results presented at meeting of the International Gynecologic Cancer Society, as per Mateon Therapeutics media release.
    • 21 Jul 2016 Status changed from active, no longer recruiting to completed, as per Mateon Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top